Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
about
Many stimuli pull the necrotic trigger, an overviewSerum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workersPelargonium quercetorum Agnew induces apoptosis without PARP or cytokeratin 18 cleavage in non-small cell lung cancer cell linesPharmacodynamic modelling of biomarker data in oncology.Semi-nested real-time reverse transcription polymerase chain reaction methods for the successful quantitation of cytokeratin mRNA expression levels for the subtyping of non-small-cell lung carcinoma using paraffin-embedded and microdissected lung biKeratins in health and cancer: more than mere epithelial cell markersSafety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure.Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patientsPhase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.A Multiplexed Cytokeratin Analysis Using Targeted Mass Spectrometry Reveals Specific Profiles in Cancer-Related Pleural EffusionsTargeting cell death signaling in colorectal cancer: current strategies and future perspectives.The transformation in biomarker detection and management of drug-induced liver injuryThe M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18.Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cells.Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model.A mutation in keratin 18 that causes caspase-digestion resistance protects homozygous transgenic mice from hepatic apoptosis and injury.Increased phosphorylation of ERK1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma.A potential association between Helicobacter pylori CagA EPIYA and multimerization motifs with cytokeratin 18 cleavage rate during early apoptosis.Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.The oxidant/antioxidant status and cell death mode in oral squamous cell carcinoma.
P2860
Q24613714-E760D2D9-A35E-4BE8-BE91-5C5AE69CBD9EQ28392515-493487BD-9E07-4223-92D6-800C48187AE1Q28829623-448CB74F-3294-4179-9D14-5F8BC3043CC9Q34241935-2C7F1410-CEED-4116-9512-860F4EC24D89Q34747336-049BCBA1-421D-42B2-B405-E4A0E9AC7520Q35161934-2CE0C559-C126-4301-8360-61A9CA4D73DFQ35193374-159D264D-F331-4201-B042-503E439C48D5Q35998447-F2ED939E-7C8D-4987-A5F5-0F0847A55BBAQ36098872-AC7CC3FB-AB87-405E-AAB0-DF4E1B95B4DDQ36177752-CDEEDB94-AAFA-496E-AC40-957F09151C3FQ36825455-7ADC36A2-79C6-43C0-90A9-88166193EFE3Q37112709-C8B2B849-E7DA-44EC-9563-C8F639335142Q37602717-70833DB8-72BE-4C86-81BF-8B128348AA0AQ38848580-72B7C2BB-9DA1-4576-A085-0CD963D52328Q38890416-9213929E-8F87-40A6-A99D-697F7DF692EEQ42152734-9E0A8878-5694-414E-8C14-5B5C67F83C03Q42263059-A635F68F-AC2B-49EC-AEF9-06917061804AQ42621191-51138E22-FC24-41BE-9F63-A682F6F2604DQ48290523-2034BC0D-B0E9-4FDE-B1CE-E67832A5CF1FQ51562158-12750F19-2C8C-4BB9-A394-D50CB1E605FAQ52629636-A5C04969-ECDF-4C56-8970-074CDC8A0B87Q52862319-410720B6-0BD3-4779-81E3-089B76164221Q53283602-78C5E19D-C3F5-4988-B81F-11343C571D72
P2860
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@en
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@nl
type
label
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@en
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@nl
prefLabel
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@en
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@nl
P2093
P2860
P356
P1476
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
@en
P2093
Engin Ulukaya
Maria Hägg Olofsson
Richard Herrmann
P2860
P304
P356
10.1586/ERM.10.14
P50
P577
2010-04-01T00:00:00Z